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Abstract
Introduction
Cervical cancer imposes a substantial health burden worldwide including in Australia and is
caused by persistent infection with one of 13 sexually transmitted high-risk human papillo-
mavirus (HPV) types. The objective of this study was to assess the cost-effectiveness of
adding a nonavalent new Gardasil-9® (9vHPV) vaccine to the national immunisation sched-
ule in Australia across three different delivery strategies.
Materials and methods
The Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used
to examine the cost-effectiveness of 9vHPV vaccine introduction to prevent HPV infection.
Academic literature and anecdotal evidence were included on the demographic variables,
cervical cancer incidence and mortality, treatment costs, and vaccine delivery costs. The
incremental cost-effectiveness ratios (ICERs) were measured per disability-adjusted life
years (DALYs) averted, using the heuristic cost-effectiveness threshold defined by the
World Health Organisation (WHO). Analyses and data from international agencies were
used in scenario analysis from the health system and societal perspectives.
Results
The 9vHPV vaccination was estimated to prevent 113 new cases of cervical cancer (dis-
counted) during a 20-year period. From the health system and societal perspectives, the
9vHPV vaccination was very cost-effective in comparison with the status quo, with an ICER
of A$47,008 and A$44,678 per DALY averted, respectively, using the heuristic cost-
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effectiveness threshold level. Considering delivery strategies, the ICERs per DALY averted
were A$47,605, A$46,682, and A$46,738 for school, health facilities, and outreach-based
vaccination programs from the health system perspective, wherein, from the societal per-
spective, the ICERs per DALY averted were A$46,378, A$43,729, A$43,930, respectively.
All estimates of ICERs fell below the threshold level (A$73,267).
Conclusions
This cost-effectiveness evaluation suggests that the routine two-dose 9vHPV vaccination
strategy of preadolescent girls against HPV is very cost-effective in Australia from both the
health system and societal perspectives. If equally priced, the 9vHPV option is the most eco-
nomically viable vaccine. Overall, this analysis seeks to contribute to an evidence-based
recommendation about the new 9vHPV vaccination in the national immunisation program in
Australia.
Introduction
Cervical cancer is both a leading cancer and the leading cause of cancer deaths in women glob-
ally [1]. An estimated 570,000 new cases of cervical cancer were diagnosed in 2018, composing
6.6% of all cancers in women [1]. In Australia, over the last couple of years, the age-specific
cervical cancer incidence has slightly reduced to 7.1 cases per 100,000 females in 2018 from 7.4
cases per 100,000 females in 2014 [2]. However, the incidence is quite high among young adult
females at 15.0 cases per 100,000 females and was the most frequently diagnosed cancer
among women in 2018 [2]. Persistent infections with human papillomavirus (HPV) are a key
cause of cervical cancer and an established carcinogen of cervical cancer [3]. HPV is predomi-
nantly transmitted to reproductive-aged women through sexual contact [4]. Most HPV infec-
tions are transient and can be cleared up within a short duration, usually a few months after
their acquisition. However, HPV infections can continue and evolve in cancer in some cases.
There are more than 100 types of HPV infections that have been identified and divided into
low- and high-risk types develop into cervical cancer [5]. Thirteen high-risk HPV types are
known to be predominantly responsible for malignant and premalignant lesions of the ano-
genital area [6] and are the leading causes of most aggressive cervical cancers [7]. Further,
HPV is also responsible for the majority of anogenital cervical cancers such as anal cancers
(88%), vulvar cancers (43%), invasive vaginal carcinomas (70%), and all penile cancers (50%)
globally [5]. The incidence of neck and head cancers caused by HPV infection is low but not
negligible [8]. Cervical cancer is preventable through implementation of a primary prevention
strategy such as vaccination worldwide including Australia [9,10]. Therefore, a reduction in
cervical cancer incidence and associated cancer mortality along with the improvement of sur-
vival rates have the potential to reduce the burden of cervical cancer.
The high burden of cervical cancer in terms of incidence and associated mortality rates
across the world could be reduced by incorporating a comprehensive primary prevention
mechanism. Prevention mechanisms includes early vaccination, diagnosis, effective screening,
adequate referral and advanced course of treatment procedures. In this context, HPV vaccina-
tions (i.e., bivalent and quadrivalent) has been introduced in many countries in the past decade
[10]. Currently, available HPV vaccines can promote herd immunity against cancer-causing
types of HPV that helps to reduce the high-risk of cervical cancer burden. These vaccines have
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played a significant role in preventing HPV infection types 16 and 18 [10], which cause more
than 70% of cervical cancers in Australia [7].
Australia was the first country to implement a publicly-funded National HPV Immunisa-
tion Program (NHIP), starting with preadolescent girls in 2007, using the quadrivalent
Gardasil1 vaccine (4vHPV; Merck & Co., Kenilworth, NJ, USA) [11]. The goals of the immu-
nisation program were to reduce the acquisition and spread of HPV infections and to achieve
optimum coverage through the school-based delivery system [12]. This program for adolescent
employed a three-dose schedule of the 4vHPV vaccine [13]. The 4vHPV vaccine provides pro-
tection against HPV infection types 6, 11, 16, and 18 [14]. In the context of Australia, the
4vHPV vaccine was replaced by the two-dose nonavalent Gardasil1-9 vaccine (9vHPV;
Merck Sharp & Dohme) in 2018 [15]. According to the underlying distribution of HPV infec-
tion types of cervical cancers, the 9vHPV vaccine builds population-level strong immunity
against HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58 infections [6] that cumulatively contribute to
approximately 89% of all cervical cancers globally [16] and 93% in Australia [17]. Considering
the primary prevention of HPV infection, the 9vHPV vaccine is anticipated to reduce by 10%
more the lifetime risk of diagnosis of cervical cancer in immunised cohorts than the 4vHPV
vaccine and by 52% more compared to non-vaccinated cohorts [18].
With the availability of vaccines against the different HPV infection types, there are good
opportunities for primary prevention to add to continuing efforts on secondary prevention
strategies. However, the decision for any country to add a new vaccine to national immuniza-
tion programs requires careful assessment of the relative value of the vaccine compared with
alternative uses of the required resources (i.e., cost-effectiveness) and its affordability (i.e., bud-
getary impact). Cost-effectiveness analysis (CEA) is a pragmatic approach which aims to exam-
ine the outcomes and costs of interventions or programs designed to improve health. CEA
evolves measuring the net or incremental costs and effects of an intervention or program in
terms of costs and health outcomes as compared with some comparator. There is considerable
evidence of assessing the cost-effectiveness of the 9vHPV vaccine in different country settings.
In Canada, the 9vHPV was found to be highly cost-effective compared with the 4vHPV vaccine
taking into consideration the shorter duration of protection (9vHPV = 20 years vs. 4vHPV =
lifelong), along with a lower vaccine efficacy (85% vs. 95%) [19]. In other studies conducted in
the United States (US), the 9vHPV vaccine was also found to be very cost-effective compared
to the 4vHPV vaccine [20]. However, findings from cost-effective evaluations will differ based
on study settings, funding, perspectives and coverage of vaccination For example, in the US,
Chesson et al. (2016) found that the 9vHPV vaccine was not cost-effective, with an incremental
cost-effectiveness ratio (ICER) of $146,200 per quality-adjusted life year (QALY) gained that
exceeded the cost-effectiveness threshold ($100,000) [21]. Some cost-effective evaluations were
performed using the same vaccine (i.e., 9-valent) in the US to capture the different dimensions
of its economic viability [22–27]. These studies incorporated different study participants,
designs, perspectives, vaccine delivery routes and model specifications. Simms et al. (2016)
evaluated the 9vHPV vaccine in a primary HPV screening scenario in both Australia and Can-
ada [18]. They found that 9vHPV had a significant impact on reducing cervical cancer inci-
dence from the health system perspective. Further, they claimed that the incremental cost per
dose in girls should not exceed a median of A$35.99. However, this study emphasised the
impact of vaccines to prevent cervical cancer rather than their economic viability. Sufficient
evidence did not arise for health policymakers to use the findings to develop cost-effective
intervention strategies. In Germany, universal immunisation with 9vHPV was suggested as it
had an ICER of €22,987/QALY gained, which was below the threshold [28]. In Spain, a recent
study evaluated a vaccine program in adolescent girls, wherein the 9vHPV vaccine was found
to be more highly cost-effective, with an ICER of €7,718 per QALY compared to the 4vHPV
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vaccine [29]. In the African setting, in Kenya and Uganda, a study recommended that the
9vHPV vaccine was very cost-effective in both countries, wherein the additional cost of the
9vHPV vaccine did not exceed I$8.3 per immunised girl [30].
In Australia, the 9vHPV vaccine was introduced in 2018. There is limited current compre-
hensive evidence about the cost-effectiveness of the 9vHPV vaccine in Australia across delivery
strategies (e.g., school-based, health facility-based and outreach-based) from the health system
and societal perspectives. The present study evaluates the cost-effectiveness of the 9vHPV vac-
cine from both health system and societal perspectives across three delivery routes. However,
the previous cost-effective evaluation considered only one perspective nor health system or
societal, or both perspectives along with single vaccine delivery route. Further, the findings of
the present study will provide evidence about the cost-effectiveness of the 9vHPV vaccine to
policymakers. These cost-effectiveness findings will also be significant for determining the
optimal pricing of delivery strategies in the vaccination program in order to maximise the soci-
etal benefits of the introduction of the new 9vHPV vaccine to Australia.
The objectives of this study are (1) to examine the cost-effectiveness of the 9vHPV vaccine
by considering three different vaccine delivery strategies in the setting of Australia from the
health system and societal perspectives and (2) compare the ICER per case, disability-adjusted
life years (DALYs), and life-years saved across delivery strategies such as school-based, health
facility-based, and outreach-based programs.
Materials and methods
Study perspective
This study was designed from both the health system and societal perspectives. The societal per-
spective refers to all types of costs that can be identified, quantified, estimated, and valued no
matter who incurred them and it is considered to be the summation of both provider and house-
hold costs. This is the recommended standard for undertaking cost-effectiveness analysis [31].
Model overview
The study used the Papillomavirus Rapid Interface for Modelling and Economics (PRIME)
model. PRIME is a user-friendly model designed and developed by the World Health Organi-
sation (WHO) in collaboration with the Johns Hopkins Bloomberg School of Public Health in
Baltimore, the School of Hygiene and Tropical Medicine in London, and the Universite Laval
in Quebec [10]. PRIME is a Microsoft Excel based (Microsoft Corp., Armonk, NY, USA) static
model that measures the health and economic effects of the vaccination of adolescent girls
against HPV infection. It is not designed to examine other dimensions, such as immunised
males or older women or the impact of cervical cancer screening services [10]. Several spread-
sheets are contained in this model to input different parameter-level data on demographics, an
age-dependent incidence of cervical cancer, associated mortality, vaccine efficacy, vaccine cov-
erage, and associated costs (e.g., vaccination costs, treatment costs). This model does not con-
sider indirect effects like herd immunity.
Methodological assumptions
Methodological assumptions follow the WHO guidelines for cost-effectiveness analysis [32].
The use of cost-effectiveness analysis is recommended when considering health system and
societal perspectives. In the context of the health system perspective, the average cost parame-
ters associated with treating a woman with cervical cancer (per episode, over the lifetime), and
the cost of the HPV vaccination program were both considered. From the societal viewpoint,
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both direct medical (e.g., drugs, diagnostics) and non-medical (e.g., transportation) costs as
well as indirect costs (e.g., productivity loses or income loss due to cervical cancer) were con-
sidered in the analysis. All future costs and health benefits were adjusted by a discount rate of
5% annually [5,29,32], which was validated in the sensitivity analysis. The primary outcome
measure is the ICERs per DALYs averted. DALY estimation was undertaken by summing up
the fatal burden (years of life lost; YLL) due to premature cervical cancer related mortality and
the non-fatal burden (years lost due to disability; YLD) for patients surviving the condition.
DALY ¼ YLLþ YLD ð1Þ
YLL ¼
N
r
1   e  rLð Þ ð2Þ
YLD ¼ I � DW � L
1   e  rL
r
� �
ð3Þ
where, N = number of deaths; L (YLL) = standard life expectancy at the age of death in that
year; I = number of people with cervical cancer cases; DW = disability weight; r = discount
rate; and L (YLD) = duration of disability in years.
Cost-effectiveness analysis
The performance of competing strategies was explained using the ICER which were calculated
by dividing the difference in cost with and without HPV vaccination by the difference in health
outcomes (e.g., the number of DALYs averted, the number of deaths and cases averted) with
and without vaccination in Australia. The ICER is used to examine whether the 9vHPV vaccine
is economically viable in Australia. In the context of Australia, no explicit cost-effectiveness
threshold has been approved [33,34], although research has confirmed that there is a correla-
tion between the incremental cost per health outcomes (e.g., QALY gained or DALY averted)
and the probability of rejection of a health intervention or a new medicine [35]. The pharma-
ceutical industry claim that an acceptable threshold was in the range of AUD 45,000 to AUD
60,000 per additional QALY gained [36]. Some studies also stated that “Pharmaceutical Bene-
fits Advisory Committee (PBAC) decisions in the past have shown that the ICER per QALY
gained was of the order of $50,000” [18,37]. The present study intended to evaluate the cost-
effectiveness of the 9vHPV vaccine in terms of the ICER per DALYs averted. Further, DALYs
and QALYs differ in concept and application. The concept of DALYs was used to measure the
disease burden using life lost due to premature death and the time spent in worse healthy
states. Empirical evidence in the Australian context is limited to the use of the willingness-to-
pay (WTP) threshold values for the ICER per DALYs averted. In reporting the cost-effective-
ness scenario, the present study used the heuristic cost-effectiveness threshold as defined by
the WHO Commission on Macroeconomics and Health (CMH) [38]. The gross domestic
product (GDP)-related cost-effectiveness thresholds were based on assumptions about leisure
time, non-health consumption, longevity and health-related quality of life. An intervention is
cost-effective if the ICER per DALY averted is less than three times of a country’s annual per
capita GDP. According to this guideline, the CMH recommended three broad decision rules,
as follows: (1) a program or intervention is defined as very cost-effective if the ICER per DALY
averted is less than one time the GDP per capita; (2) a program or intervention is cost-effective
if the ICER per DALY averted is one or more times the GDP per capita but less than or equal to
three times the GDP per capita; and (3) a program or intervention is not cost-effective if the
ICER per DALY averted is more than three times the GDP per capita [31].
The cost-effectiveness of 9-valent human papillomavirus vaccine among school-aged girls in Australia
PLOS ONE | https://doi.org/10.1371/journal.pone.0223658 October 9, 2019 5 / 18
Vaccine and efficacy
The Australian Technical Advisory Group on Immunisation (ATAGI) in 2018 advised moving
from using the quadrivalent 4vHPV to using the nonavalent Gardasil-9 (9vHPV) vaccine [39].
The 9vHPV vaccine has been registered for use in Australia [40]. The vaccine is funded
through the national immunisation program (NIP) and delivered primarily by state and terri-
tory school-based immunisation programs in Australia [39]. This vaccine is manufactured
using a procedure similar to that of the 4vHPV vaccine, which contains 0.5mg of aluminium
hydroxyphosphate sulphate and a yeast expression system [40]. The 4vHPV vaccine contains
five more virus-like particles than the original vaccine, identical to those in the protective cap-
sule around the nine included strains (HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58) with the aim to
further reduce the HPV disease burden. The high prophylactic efficacy of the 9vHPV vaccine
(93%) against HPV infection is evident both in Australia (77% for HPV types 16, 18 and 16%
for HPV types 6, 31, 33, 45, 52, 58) [17] and globally (89%) [16]. However, no herd immunity
was considered. It was recommended for the target cohort of adolescents aged 12 years to
receive a two-dose 9vHPV vaccination for several reasons [39]. First, administering a vaccina-
tion at this age is more likely to ensure it is being given before their first sexual encounter (and
HPV exposure). Also, the immune response tends to be stronger and more long-lasting when
the vaccine is given to pre-adolescents. However, 9vHPV is not recommended for use during
pregnancy. Similarly, vaccination is delayed if the person is unwell or has a high temperature,
medical advice is recommended if the person is allergic to yeast or has had a severe reaction to
a previous vaccine, and anyone who receives the vaccine is recommended to sit for 15 minutes
thereafter to reduce the risk of fainting.
Vaccine delivery strategies
The HPV vaccine delivery strategy is an important aspect that needs to be considered carefully
by each country. According to the country-specific context, the costs of vaccine delivery may
vary. The WHO has recommended several types of common vaccine delivery strategies for dif-
ferent country settings. One example is vaccine delivery at healthcare facilities and via outreach
routes (e.g. school-based program) and campaigns. It may be required to use a combined vac-
cine delivery strategy to ensure access among the entire target population. The 9vHPV vaccine
has been delivered in Australia through school-based NIP in all states and territories to the tar-
get population cohort of school-going adolescents since January 2018. Two doses of 9vHPV
are recommended to be administered at a minimum interval of six to 12 months between
doses [39]. In some cases, general practitioner (GP) and other primary health care providers
are generally engaged to catch up doses missed in the routinely school-based NIP. All provid-
ers are proactively involved in delivering and ensuring the completion of all doses of the
9vHPV vaccine to those individuals with special requirements, vaccine hesitancy, or immuno-
compromise. However, individuals who have already been fully immunised with HPV vac-
cines are not eligible for free 9vHPV vaccination. The present study incorporated another two
hypothetical vaccine delivery strategies, as health facility-based and outreach-based, both from
the health system and societal perspectives.
Vaccine delivery costs
The present study considered vaccine delivery related costs across three delivery strategies
(e.g., school-based, health facility-based and outreach-based). Costs were derived from an
existing costing study [41]. This study captured both financial and economic costs according
to the WHO guidelines [42], included eight cost parameters, and focused on the investment
and recurrent cost impacts of HPV vaccination on existing vaccination services. Furthermore,
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the investment costs were defined as microplanning (e.g., per diems and travel allowances,
venue rental, transport and personnel time spent), training (e.g., training materials, statio-
nery), social mobilisation (e.g., facilitator time in meetings, production of television/radio
spots, posters, leaflets, value of teacher and volunteer time), and cold chain supplement. In
addition, recurrent costs were covered including vaccines, service delivery, monitoring and
evaluation, and waste disposal.
Cervical cancer treatment costs
Direct medical costs. Cervical cancer treatment costs were derived from a previous cost-
of-illness study considering four treatment procedures: localised cancer treatment, regional
cancer treatment, distant cancer treatment and terminal care [43]. The treatment costs were
estimated based on different parameters such as surgical (e.g., conisation, hysterectomy, radi-
cal hysterectomy) and non-surgical (e.g., radiation therapy, adjuvant radiation therapy,
chemo-radiation) [43]. Different types of activities included in cancer diagnosis were the direct
medical costs such as colposcopy, chest X-ray, computerised tomography scan, positron-emis-
sion tomography scan, magnetic resonance imaging, bone scan and cystoscopy. Other costs
included those related to inpatient care, emergency care, medicine costs, rehab, complex con-
tinuing care, long-term care, home care services, physician consultations, and non-physician
provider costs.
Indirect costs. Indirect costs of cervical cancer patients and vaccine receivers were
restricted to the loss of labour productivity due to ill health. Absenteeism-related data were
obtained for a cervical cancer episode from elsewhere [32]. Other indirect costs were estimated
using the human capital approach (S1 Table). The production losses were measured in both
monetary and quantitative terms (e.g., days of productivity loss) [44]. The value of unpaid
time devoted to own care and family defined caregivers [45]. The value of daily productivity
was measured based on an age-specific average wage [46]. The average daily wage of cervical
cancer patients were used for adult patients, and one-half of that wage was applied to teenager
patients. Intangible costs related to pain, discomfort and grief were excluded [46]. All costs
were converted into 2018 Australian dollars using the Consumer Price Index of Health Care
[47].
Dynamic modelling of HPV transmission and the impact of vaccination. A dynamic
cancer disease model was introduced to cover HPV transmission, HPV vaccination and cervi-
cal pre-cancer (Fig 1). The model incorporates demographics, economics, HPV attributable
fractions in cervical cancer and vaccine uptake assumptions, as detailed in Table 1. When
modelling the impact of HPV vaccination, the model captured the effects of herd protection
(i.e., naturally acquired immunity) on the unvaccinated cohort. It was assumed that 9vHPV
vaccine type-specific (HPV types) efficacy in girls was 100% and that the duration of protection
was 20 years [19,27].
Sensitivity analysis. A deterministic sensitivity analysis was performed to examine the
robustness of the results. The output estimates varied for each value of the input parameters.
These prices were derived from the academic and anecdotal literature and aimed to determine
the impact of uncertainty in input assumptions on the ICERs.
Results
Model input parameters
Table 1 shows several input parameters, including the population cohort at birth, coverage of
full dose vaccine, vaccine effectiveness versus HPV-9 types, the price of vaccine, and vaccine
delivery costs per fully immunised girl. Cervical cancer treatment related costs per episode
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included direct costs (e.g., medical and non-medical costs) and indirect costs (e.g., loss of
labour productivity for patients and caregivers during treatment). DALYs incurred for nonfatal
and fatal cervical cancer episodes, and epidemiological data related to cervical cancer inci-
dence were used. The sizes of the female birth cohort and the cohort at immunisation age were
191,340 and 118,679, respectively. Vaccination coverage was 86%, whereas vaccine effective-
ness against HPV infections was 95%. The price of the vaccine and direct and indirect vaccine
delivery costs were A$280, A$31.77, and A$17.59, respectively. Cervical cancer treatment costs
were A$61,272, wherein 53.78% (A$32,952) were direct costs and 46.22% (A$28,322) indirect
costs. These varied depending on the types of treatment and stages of cancer. Cervical cancer
incidence and mortality-related data were extracted from national sources and the GLOBO-
CAN-2018 study [48]. Methodological assumptions such as disability weights (for cancer diag-
nosis, non-terminal and terminal) are shown in Table 1. Vaccine protection was considered to
be 20 years as suggested by an expert panel and earlier research [49].
Cost-effectiveness estimates
The model estimates in Table 2 show the cost-effectiveness of the 9vHPV vaccination in Aus-
tralia under various assumptions about the cost of cervical cancer treatment and the cost of
vaccination across delivery strategies. The 9vHPV vaccination in Australia would cost the pub-
lic approximately A$28.11 million for this target population cohort, although several types of
treatment procedures would be transferred from the health system perspective and the value
of A$26.72 million from a societal perspective across the various vaccine delivery strategies
(e.g., school-based, health facility-based, outreach-based) would result. State and territory
school-based immunisation programs primarily implement the 9vHPV vaccination through
the NIP in Australia. Another two possible delivery strategies (e.g., health facility-based and
outreach-based) were also included for comparison. Overall, the ICER per DALY averted was
A$47,008 from a health system perspective and A$44,678 from a societal perspective, respec-
tively. Considering delivery strategies, the ICERs per DALY averted were A$47,605, $46,682
and $46,738 for school-based, health facility-based and outreach-based programs, respectively,
from the health system perspective. Whereas, from the societal perspective, the values were A
$46,378, A$43,729, and A$43,930 respectively. Both perspectives for ICERs per DALY averted
fell below the 2018 fiscal year GDP per capita in Australia (A$73,267), which is used as a
Fig 1. Simplified diagram of the model of HPV transmission, human impact of vaccination and disease outcomes
in Australia.
https://doi.org/10.1371/journal.pone.0223658.g001
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threshold for examining the cost-effectiveness of an intervention. Similarly, consistent results
were presented for the ICERs per life-year saved for both perspectives across delivery strategies
(Table 2). This evaluation signifies the cost-effectiveness of the 9vHPV vaccination from both
perspectives in Australia.
Table 1. Input parameter assumptions and sensitivity analysis.
Input parameters Health system perspective Societal perspective
Sensitivity analysis and
potential sources
Overall School-
based
Health
facilities-
based
Outreach-
based
Overall School-
based
Health
facilities-
based
Outreach-
based
Population
Population cohort at birth
(female) (‘000)
191.34 191.34 191.34 191.34 191.34 191.34 191.34 191.34 [50]
Population cohort at
vaccination age (female)
(‘000)
118.68 118.68 118.68 118.68 118.68 118.68 118.68 118.68
[40,51]
Target age group (yrs) 12 12 12 12 12 12 12 12 [39]
Vaccination and vaccine delivery costs
Vaccination coverage (full
doses)
86% 86% 86% 86% 86% 86% 86% 86% 72.00% -90.1% [51–55]
Vaccine effectiveness vs
HPV types1
95% 95% 95% 95% 95% 95% 95% 95% 85% -100% [25,52,53,56]
Price of vaccine per fully
immunised girl (FIG) (A$)
280 280 280 280 280 280 280 280 270–320 [32,41,57]
Direct costs of vaccine
delivery per FIG (A$)
31.77 35.27 29.86 30.19 31.77 35.27 29.86 30.19 [5,32,41]
Indirect costs of vaccine
delivery per FIG (A$)
- - - - 17.59 24.05 13.93 14.79
Total cost of vaccine
delivery cost per FIG (A$)
31.77 35.27 29.86 30.19 49.36 59.32 43.80 44.98
Total costs of vaccination
per FIG (A$)
311.77 315.27 309.86 310.19 329.36 339.32 323.80 324.98 300–500 [5,32,41]
Treatment cost per episode
Direct costs A$ (‘000) 32.95 32.95 32.95 32.95 32.95 32.95 32.95 32.95 [32,43]
Indirect costs (including
caregiver costs) A$ (‘000)
- - - - 28.32 28.32 28.32 28.32 [32,43]
Total treatment costs A$
(‘000)
32.95 32.95 32.95 32.95 61.27 61.27 61.27 61.27 36.05–71.05 [32,43]
Methodological assumptions
Disability weight for cancer
diagnosis
0.09 0.09 0.09 0.09 0.07 0.09 0.09 0.09 0.061–0.095 [10,32,58,59]
Disability weight for non-
terminal (per year)
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.065–0.091 [10,32]
Disability weight for
terminal cancer
0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.70–0.90 (assumption)
Vaccine protection (years) 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 yrs 20 years [19]
Discount rate 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 5.0% 3.0% -5.0%
[23,24,30,32,58,60]
Proportion of cervical
cancer cases that are
due to 1HPV-types
90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 90.3% 70% -95.0% [9,15,17,39]
Economic growth
GDP per capita, A$ 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267 [61]
1HPV-6, 11, 16,18,31,33,45,52,58
https://doi.org/10.1371/journal.pone.0223658.t001
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Table 2. Outcomes of the vaccination program�.
Scenario Scenario– 1 Scenario—2
Perspective Health system perspective Societal perspective
Vaccine delivery strategies Overall School-
based
Health facilities-
based
Outreach-
based
Overall School-
based
Health
facilities-
based
Outreach-
based
Output parameters
Cohort size at birth (female), (‘000) 191.34 191.34 191.34 191.34 191.34 191.34 191.34 191.34
Cohort size at vaccination age (female)
(‘000)
118.68 118.68 118.68 118.68 118.68 118.68 118.68 118.68
Total costs of vaccination, A$ (‘000) 31,820.48 32,177.70 31,625.53 31,659.21 33,615.78 34,632.34 33,048.30 33,168.74
Total treatment costs averted, A$ (‘000) 3,709.75 3,709.75 3,709.75 3,709.75 6,898.41 6,898.41 6,898.41 6,898.41
Net costs of the vaccination, A$ (‘000) 28,110.73 28,467.95 27,915.78 27,949.47 26,717.37 27,733.93 26,149.90 26,270.33
Number of averted-
- Cervical cancers case averted 113 113 113 113 113 113 113 113
- Deaths averted 23 23 23 23 23 23 23 23
- Life years saved 543 543 543 543 543 543 543 543
Nonfatal DALYs averted 55 55 55 55 55 55 55 55
Incremental cost-effectiveness ratio
(ICER) per-
- Cervical cancers case averted, A$ 248,767 251,929 247,042 247,340 236,437 245,433 231,415 232,481
- Life saved, A$ 1,222,205 1,237,737 1,213,730 1,215,194 1,161,625 1,205,823 1,136,952 1,142,188
- Life year saved1, A$ 51,769 52,427 51,410 51,472 49,203 51,075 48,158 48,380
- DALYs averted1, A$ 47,008 47,605 46,682 46,738 44,678 46,378 43,729 43,930
Cost-effectiveness threshold
GDP per capita, A$ 73,267 73,267 73,267 73,267 73,267 73,267 73,267 73,267
Decision rules
- Very cost-effective1 Yes Yes Yes Yes Yes Yes Yes Yes
- Cost-effective2
- No cost-effective3
1Very cost-effective if ICER per DALYs averted< 1 time GDP per capita
2cost-effective if ICER per DALYs averted� 1 times GDP per capita and� 3 times GDP per capita
3no cost-effective if ICER per DALYs averted> 3 times GDP per capita.
�Costs and DALYs were discounted at 5% per year.
https://doi.org/10.1371/journal.pone.0223658.t002
Fig 2. Changes in input model parameters on ICER per DALY averted from a health system perspective.
https://doi.org/10.1371/journal.pone.0223658.g002
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Sensitivity analysis
Model uncertainty was investigated by changing the values of input parameters in the cost-
effectiveness model from the health system (Fig 2) and societal perspectives (Fig 3). The output
of the deterministic sensitivity analysis showed that the price of vaccine, vaccine delivery costs,
the incidence of cervical cancer, vaccination coverage, vaccine efficacy, and cervical cancer
treatment costs were the dominating parameters that influence the ICERs per DALY averted.
These findings are conservative, as only a simple static model of 9vHPV vaccination was con-
sidered. According to the WHO-CHOICE threshold, the 9vHPV vaccination is a very cost-
effective and favourable option for introduction in Australia. This analysis indicates that the
model outputs are robust to variation in the values of all parameters; however, there is a neces-
sity to confirm that the pricing of the vaccine is appropriate in the context of Australia.
Discussion
The present study is a comprehensive cost-effectiveness evaluation of the introduction of a
NIP with the new 9vHPV vaccine to adolescent girls in Australia. The impact of 9vHPV vacci-
nation on health and economic outcomes was measured using various model scenarios allow-
ing for the testing of three different vaccine delivery strategies.
The findings show that the new 9-valent vaccination of 12-year-old adolescent girls is highly
cost-effective, with ICERs per DALY of A$47,008 and A$44,678, from the health system and
societal perspectives, respectively. Although the 9vHPV vaccination has been implemented as
part of the school-based delivery strategy, the present study has emphasised two other hypo-
thetical delivery strategies, namely health facility-based and outreach-based programs. If the
9vHPV vaccination program is extended to these delivery outlets, the ICER remains highly
cost-effective at A$46,682/DALY averted for health facility-based and A$46,738/DALY averted
for outreach-based vaccination programs compared with a school-based vaccination program
(ICER = A$47,605/DALY averted). Considering the societal perspective, the 9vHPV vaccina-
tion also reports a very cost-effective outcome, with an ICER of A$46,378/DALY averted, A
$43,729/DALY averted, and A$43,930/DALY averted for the school-based, health facility-
based and outreach-based vaccination programs, respectively. It is noteworthy that the ICERs
are comparatively lower from the societal perspective in terms of vaccine delivery strategies
compared with the health system perspective.
Immunisation would still be very cost-effective from both the health system and societal
perspectives if the program is extended to encompass other delivery strategies. However, no
herd immunity was considered in the context of these strategies. This evaluation provides a
piece of initial evidence for the value of money of investments in the 9vHPV vaccination and
protection against transient and persistent infections of HPV. Under the input model
Fig 3. Changes in input model parameters on ICER per DALY averted from a societal perspective.
https://doi.org/10.1371/journal.pone.0223658.g003
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assumptions, the present evaluation of the two-dose 9vHPV vaccination would be very cost-
effective across delivery strategies. From the societal perspective, the ICER per DALYs averted
was comparatively lower than the health system perspective in terms of delivery strategies. The
cost-effectiveness evaluation is significant even allowing for different vaccine delivery strate-
gies and vaccination model assumptions.
This study findings are consistent with the conclusions from the evaluation of cost-effec-
tiveness of the 9vHPV vaccination in other country settings including Austria [62], Canada
[19], Germany [28], Italy [5], Kenya and Uganda [30], South Africa [52], and the US [21,63].
These studies estimated that an immunisation programs with the 9vHPV vaccine was likely to
belong within an acceptance heuristic threshold level of cost-effectiveness or even reach cost-
saving status in different country settings. In Canada, the 9vHPV vaccine was offered to
school-aged girls and evidenced to be cost-effective at a price increment lower than CAN$24
[19]. Further, 9vHPV was found to be cost-effective in the US, if the incremental cost per dose
of the 9vHPV was less than US$13 for a gender-neutral strategy (school-aged girls only) from a
health system perspective [64]. From a societal perspective, the 9vHPV vaccine would also be
considered very cost-effective at the national and state levels in the US if the vaccine price of
9vHPV was US$148 per dose (in 2016) [65], whereas two-dose schedules of the 9vHPV vaccine
were likely more cost-efficient compared with three-dose schedules considering the popula-
tion-level effectiveness [18]. Another recent study showed that introducing a universal 9vHPV
vaccination in Germany would yield noteworthy incremental public health benefits and be
highly cost-effective [28].
The present evaluation was performed among school-aged preadolescent girls (i.e., 12 years
of age). Previous studies confirmed that vaccination of girls only was commonly more effective
versus vaccination of both genders in different settings [28,32]. The two-dose 9vHPV vaccina-
tion approach is recommended for the target cohort of adolescent girls aged 12 to 14 years for
several reasons [39]. Giving the vaccination at this age is likely to ensure immunization before
their first sexual encounter and HPV exposure. As a result, the immune response tends to be
stronger and more long-lasting when the vaccine is present in preadolescent girls. A vaccina-
tion schedule against HPV would allow for a more efficient primary strategy by protecting
females exposed to male partners and unvaccinated females to prevent HPV transmission
[9,28,63]. Eventually it would provide additional benefits to potentially accomplish virus eradi-
cation [28].
Most previous studies pay little attention to comparing the cost-effectiveness from the
health system and societal point of views across vaccine delivery strategies. Thus, the evidence
produced is not sufficient for health policymakers to decide upon effective or conclusive strate-
gies. This study findings however provides effective and efficient empirical evidence of its eco-
nomic viability. Health policymakers can use this evidence for the allocation of health
resources and extend their vaccination program to other country settings to ensure optimal
health gains.
This study has some strengths that should be highlighted. This vaccination is justified over-
all by epidemiological and health and economic outcomes. Under the input model assump-
tions, this study demonstrates that the 9vHPV vaccination is economically viable from both
the health system and societal perspectives. A broader societal perspective calculates additional
benefits of the new vaccine that are mainly associated with reduced productivity losses. HPV-
related cervical lesions lead to a loss or reduction of women’s household income due to high
productivity loss (presenteeism) and absenteeism [66]. Ultimately, HPV related diseases lead
to a decrease in a victim’s socioeconomic position, which is costly for working women, their
employers, and the economy. The study findings show distinctly that three vaccine delivery
strategies (e.g., school-based, health facilities and outreach-based) are cost-effective. This is
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significant for health policymakers, strategic leaders, health scientists, cancer experts and pub-
lic health professionals to help promote further implementation and extension of vaccination
via a universal immunisation strategy.
This study also has some caveats. Little evidence is available on the health and economic
burden of cervical cancer in Australia. Some of the model parameters related to indirect costs
for cervical cancer treatment and costs of vaccination across vaccine delivery strategies (e.g.,
school-based, health facility-based, and outreach-based) are not available for Australia. Indi-
rect costs of patients (e.g., opportunity costs) in terms of absenteeism due to cervical cancer
and caregiver time were taken from the academic literature and anecdotal evidence in Austra-
lia and international sources. In this context, the cost-of-illness study would be appropriate for
measuring the productivity losses of patients and their caregivers. However, due to a limited
timeframe it was not able to conduct a cost-of-illness study among cervical cancer patients. It
was presumed that the 9vHPV vaccine would be delivered to both boys and girls, but that it
would only be cost-effective among girls, as the direct health impacts for 9vHPV is expected to
be small for boys. This study used the GDP per capita thresholds level as defined by CMH. The
GDP threshold might be a suitable screening method but should not be the only consideration
for vaccination investment as there are other issues such as feasibility, affordability, alternative
interventions and other local considerations which are not accounted for in the threshold level
decision rule. Finally, the study findings were generated for the national context in Australia
and might vary by state or regional settings, depending on cervical cancer outcomes (e.g., inci-
dence, mortality), treatment procedures, cancer stages, costs of vaccination, and coverage of
immunisation.
Conclusions
This study is an extensive cost-effectiveness analysis of 9vHPV vaccination in Australia from
both the health system and societal perspectives. The introduction of the 9vHPV immunisation
is assessed to be very cost-effective from both perspectives. It incorporated three delivery strat-
egies (school-based, health facility-based, and outreach-based). However, this high-value vac-
cination would need substantial upfront investments. Considering a two-dose schedule, the
9vHPV vaccination demonstrated ‘good value for money’, if the vaccination could accomplish
a high vaccination coverage and provide protection. The findings of this evaluation contribute
to decision-making about the incorporation of the 9vHPV vaccine into a universal cervical
cancer vaccination program in Australia. With continued assessment of the potential vaccine
properties as well as vaccine delivery and scale-up strategies, the two-dose 9vHPV vaccine
would provide significant health and economic benefits for preadolescents and society. Finally,
the success of 9vHPV vaccination will be contingent on several predominating factors includ-
ing value for money, feasibility, acceptability, and affordability.
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